What they make
2 inputs Grünenthal PRO supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Grünenthal PRO makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Branded Pain Portfolio
50%Grünenthal PRO (CDMO)
30%R&D and Licensing
12%LatAm and Emerging Markets
8%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Origin2012
Grünenthal GmbH — the Aachen-based private family company operating Grünenthal PRO as a trusted CDMO for controlled substance APIs — is the same company that developed and marketed thalidomide (Contergan) in West Germany from 1957 to 1961. Thalidomide caused severe limb reduction defects in an estimated 10,000 to 20,000 babies worldwide. German criminal charges against Grünenthal executives were filed in 1961 and formally dropped in 1970 without conviction, after the company paid DM 100 million into a relief fund. The company has never paid court-ordered damages. The Wirtz family, which founded Grünenthal, still owns it today. When pharmaceutical companies contract Grünenthal PRO for controlled substance API manufacturing, they are sourcing from an entity whose thalidomide liability was never adjudicated.
The Guardian ↗Chokepoint2024
Grünenthal PRO's Mitlödi, Switzerland facility has produced tramadol continuously for over 30 years and delivered approximately 390 tonnes of tramadol APIs to more than 50 customers across the world in 2024 — representing roughly one-third of global tramadol API output. Tramadol is the most widely prescribed opioid globally (not subject to Schedule II DEA quotas in the US, only Schedule IV), and this concentration at a single Swiss facility represents a quiet chokepoint largely overlooked by US supply chain monitoring.
Grünenthal ↗Did you know2005
Grünenthal markets ziconotide (Prialt) in Europe — a drug derived from the venom of the cone snail Conus magus, one of the most venomous marine creatures on Earth. Ziconotide is a 25-amino-acid peptide (ω-conotoxin MVIIA) that must be delivered via intrathecal pump directly into the spinal fluid; it cannot be taken orally or injected systemically because it does not cross the blood-brain barrier. It is used exclusively for patients with severe, refractory chronic pain who have exhausted all other options including high-dose opioids. Grünenthal acquired EU marketing rights from Jazz Pharmaceuticals. The same company that invented tramadol (a synthetic central-acting opioid) also markets a drug harvested from cone snail venom for patients for whom tramadol is no longer effective.
European Medicines Agency ↗Capacity2023
Grünenthal PRO operates controlled substance API manufacturing under German BtMG (Betäubungsmittelgesetz — Narcotic Drugs Act) authorization and is certified to manufacture DEA-scheduled APIs for export to US pharmaceutical companies. As one of the few European GMP-certified CDMOs with full controlled substance capability across the BtMG/Schedule I-IV spectrum, Grünenthal PRO holds a structural competitive advantage: European regulatory environments accept German BtMG compliance as equivalent to US Schedule requirements, giving Grünenthal PRO access to both markets from a single facility. They compete primarily with Noramco (US), Siegfried (Switzerland), and Cambrex/Thermo Fisher for opioid CDMO work.
Grünenthal GmbH ↗